Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K



SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today the filing of its Form 10-K annual report with the United States Securities and Exchange Commission (“SEC”) for the year-ended December 31, 2023. 

The annual report can be accessed on the SEC’s website at or on the Company’s website at under the “investors” section.

Post Year-End 2023 Event

On January 31, 2024, the Company completed a 1-for-40 reverse split of its common stock.  As a result, the Company’s common shares currently trade under the symbol “SIGYD” and will revert back to the trading symbol “SIGY” on February 29, 2024.  At present, the Company reports 1,224,315 shares of its common stock to be issued and outstanding.

Summary of 2023 Events

During 2023, Sigyn Therapeutics expanded its line-up of therapeutic candidates to enhance the performance of cancer therapies through the introduction of ImmunePrepTM, a platform technology to improve the delivery of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs.

Additionally, the Company is developing ChemoPrepTM, a medical technology to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, and ChemoPureTM to extract off-target chemotherapy from the bloodstream to reduce treatment toxicity.

During the course of 2023, the Company also established the treatment protocol and identified clinical site locations for first-in-human clinical studies of Sigyn TherapyTM, a novel blood purification technology to address pathogen-associated conditions that are not treatable with drug therapies. Candidate treatment indications include drug resistant viral and bacterial infections, endotoxemia, and sepsis.

The first-in-human treatment protocol calls for the enrollment of dialysis dependent end-stage renal …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *